In this trial a partial responses was detected on 8 of 41 treated patients with this agent, concluding that the patients with GBM tumors who have high levels of EGFR expression and low levels of phosphorylated PKB/Akt had better response to erlotinib treatment than those with low levels of EGFR expression and high levels of phosphorylated PKB/Akt [3]. Here, AKT1 is linked to glioblastoma.